Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.51 |
| ▸ | PEPD | P12955 | 2/20 | 0.51 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10404526 | 0.98 | POLB (0.60) | POLBFKBP1APEPDXPNPEP1ALDH1A1 | |
| SCHEMBL3061683 | 0.94 | FKBP1A (0.57) | POLBFKBP1APEPDXPNPEP1ALDH1A1 | |
| SCHEMBL5965365 | 0.94 | FKBP1A (0.57) | POLBFKBP1APEPDXPNPEP1ALDH1A1 | |
| SCHEMBL30599979 | 0.85 | POLB (0.58) | POLBFKBP1APEPDXPNPEP1ALDH1A1 | |
| SCHEMBL14426613 | 0.85 | POLB (0.58) | POLBFKBP1APEPDXPNPEP1ALDH1A1 | |
| SCHEMBL3231796 | 0.85 | POLB (0.58) | POLBFKBP1APEPDXPNPEP1ALDH1A1 | |
| SCHEMBL468720 | 0.85 | POLB (0.58) | POLBFKBP1APEPDXPNPEP1ALDH1A1 | |
| SCHEMBL2037827 | 0.85 | POLB (0.58) | POLBFKBP1APEPDXPNPEP1ALDH1A1 | |
| SCHEMBL9546469 | 0.85 | POLB (0.58) | POLBFKBP1APEPDXPNPEP1ALDH1A1 | |
| SCHEMBL468719 | 0.85 | POLB (0.58) | POLBFKBP1APEPDXPNPEP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | SPARK BIOPHARMA, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4365175-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | Spark Biopharma, Inc. (KR) | 2024-05-08 | — | — | EP | disclosed |
| CN-117897386-A | Benzopyran derivatives and uses thereof | 斯帕克生物制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-0331130-B1 | CARBAMIC ACID ESTER OF SUBSTITUTED 7-HYDROXY-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES | NOVO NORDISK A/S (DK) | 1993-09-29 | — | — | EP | disclosed |
| US-5045540-A | Amide or urea compounds containing imidazole groups | WARNER-LAMBERT CO. (US) | 1991-09-03 | — | — | US | disclosed |
| US-5041552-A | Treatment of hypertension, heart failure, glaucoma and hyperaldosteronism | WARNER-LAMBERT COMPANY (US) | 1991-08-20 | — | — | US | disclosed |
| US-5017571-A | Prodrugs, mental disorders | NOVO NORDISK A/S (DK) | 1991-05-21 | — | — | US | disclosed |
| US-4908371-A | Pharmaceuticals | CIBA-GEIGY CORPORATION (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0075093-B1 | PROCESS FOR THE MANUFACTURE OF L-PROLINE | Degussa Aktiengesellschaft (DE) | 1984-12-05 | — | — | EP | disclosed |
| US-4469876-A | FROM ESTER OF L-PYROGLUTAMIC ACID | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1984-09-04 | — | — | US | disclosed |
| EP-0034284-B1 | PIPERAZINE DERIVATIVE, PROCESSES FOR PREPARING THE SAME AND THERAPEUTIC COMPOSITIONS CONTAINING IT | Tanabe Seiyaku Co., Ltd. (JP) | 1983-10-05 | — | — | EP | disclosed |
| EP-0075737-A1 | N-Chlorocarbonyl-amino-acid esters, process for their preparation and their use | Degussa Aktiengesellschaft (DE) | 1983-04-06 | — | — | EP | disclosed |
| EP-0075093-A1 | Process for the manufacture of L-proline | Degussa Aktiengesellschaft (DE) | 1983-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | MYD88, MYADM, CD14 | POLB 4767/4885FKBP1A 2480/4885PEPD 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.